A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ponstel Indications, Dosage, Storage, Stability - Mefenamic Acid
Ponstel Indications, Dosage, Storage, Stability - Mefenamic Acid
INDICATIONS
Ponstel is indicated:
- For relief of mild to moderate pain in patients ³14
years of age, when therapy will not exceed one week (7 days).
- For treatment of primary dysmenorrhea.
DOSAGE AND ADMINISTRATION
As with other NSAIDs, the lowest dose should be sought for each patient.
Therefore, after observing the response to initial therapy with Ponstel,
the dose and frequency should be adjusted to suit an individual patient's
needs.
Administration is by the oral route, preferably with food.
For relief of acute pain in adults and adolescents ³14
years of age, the recommended dose is 500 mg as an initial dose followed
by 250 mg every 6 hours as needed, usually not to exceed one week.4
For the treatment of primary dysmenorrhea, the recommended dose is 500
mg as an initial dose followed by 250 mg every 6 hours, starting with
the onset of bleeding and associated symptoms. Clinical studies indicate
that effective treatment can be initiated with the start of menses and
should not be necessary for more than 2 to 3 days.5
HOW SUPPLIED
Ponstel (mefenamic acid) is available as 250 mg blue-banded, ivory capsules,
imprinted with "P-D 540."
| Bottles of 100 |
N 0071-0540-24 |
Storage
Store at controlled room temperature 15°-30° C (59°-86° F). Protect from
moisture.
REFERENCES
1. Neuvonen PJ, Kivisto KT: Enhancement of drug absorption by antacids.
An unrecognized drug interaction. Clin Pharmacokinet. 27:120-8,
Aug 1994.
2. Tall AR, Mistilits SP: Studies on Ponstan (mefenamic acid): I. Gastro-intestinal
blood loss; II. Absorption and excretion of a new formulation. J Int
Med Res (UK). 1975,3(3) p176-82.
3. Winder CV, Kaump DH, Glazko et al: Experimental observations of flufenamic,
mefenamic, and meclofenamic acids. AnnPhys Med (Eng), Suppl p7-49.1967.
4. Glazko AJ: Experimental observations of flufenamic, mefenamic and
meclofenamic acids. Part III. Metabolic disposition, in Fenamates in Medicine.
A Symposium, London, 1966. Annals of Physical Medicine, Supplement,
pp 23-36, 1967.
5. Data on file, Medical Affairs Dept, Parke-Davis.
6. Budoff PW: Use of mefenamic acid in the treatment of primary dysmenorrhea.
JAMA. 241:2713-2716,1979.
7. Buchanan RA, et al. The breast milk excretion of mefenamic acid. Curr
Ther Res. 10:592,1968.
8. Corby DG, Decker WJ: Management of acute poisoning with activated
charcoal. Pediatrics. 54:324,1974.
9. Champion GD, Graham GG: Pharmacokinetics of non-steroidal anti-inflammatory
agents. Aust NZ J Med. 8 (Supp 1):94-100, Jun 1978.
10. McGurk KA, RemmeI RP, Hosagrahara VP, Tosh D, Burchell B: Reactivity
of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo.
Drug Metab Dispos. Aug 1996,24(8)p842-9.
11. Ito K, Niida Y, Sato J et al: Pharmacokinetics of mefenamic acid
in preterm infants with patent ductus arteriosus. Acta Paediatr JPN.
36(4):387-91, 1994.
Rx only
top
